v3.26.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance, beginning of period (in shares) at Dec. 31, 2024   82,734,696      
Balance, beginning of period at Dec. 31, 2024 $ 134,274 $ 8 $ 1,602,441 $ 268 $ (1,468,443)
Statement of Stockholders' Equity (Deficit)          
Issuance of common stock (in shares)   706,236      
Issuance of common stock 1,435   1,435    
Stock-based compensation expense 2,979   2,979    
Vesting of restricted common stock awards (in shares)   268,604      
Unrealized loss on marketable debt securities (180)     (180)  
Net loss (76,088)       (76,088)
Balance, end of period (in shares) at Mar. 31, 2025   83,709,536      
Balance, end of period at Mar. 31, 2025 62,420 $ 8 1,606,855 88 (1,544,531)
Balance, beginning of period (in shares) at Dec. 31, 2024   82,734,696      
Balance, beginning of period at Dec. 31, 2024 134,274 $ 8 1,602,441 268 (1,468,443)
Statement of Stockholders' Equity (Deficit)          
Unrealized loss on marketable debt securities (253)        
Net loss (129,323)        
Balance, end of period (in shares) at Jun. 30, 2025   87,388,425      
Balance, end of period at Jun. 30, 2025 19,189 $ 9 1,616,931 15 (1,597,766)
Balance, beginning of period (in shares) at Mar. 31, 2025   83,709,536      
Balance, beginning of period at Mar. 31, 2025 62,420 $ 8 1,606,855 88 (1,544,531)
Statement of Stockholders' Equity (Deficit)          
Issuance of common stock (in shares)   3,419,836      
Issuance of common stock 7,185 $ 1 7,184    
Stock-based compensation expense 2,664   2,664    
Vesting of restricted common stock awards (in shares)   102,894      
Issuance of common stock under employee stock purchase plan (in shares)   156,159      
Issuance of common stock under employee stock purchase plan 228   228    
Unrealized loss on marketable debt securities (73)     (73)  
Net loss (53,235)       (53,235)
Balance, end of period (in shares) at Jun. 30, 2025   87,388,425      
Balance, end of period at Jun. 30, 2025 19,189 $ 9 1,616,931 15 (1,597,766)
Balance, beginning of period (in shares) at Dec. 31, 2025   97,866,996      
Balance, beginning of period at Dec. 31, 2025 27,288 $ 10 1,655,781 0 (1,628,503)
Statement of Stockholders' Equity (Deficit)          
Stock-based compensation expense 2,102   2,102    
Vesting of restricted common stock awards (in shares)   34,038      
Net loss (24,982)       (24,982)
Balance, end of period (in shares) at Mar. 31, 2026   97,901,034      
Balance, end of period at Mar. 31, 2026 4,408 $ 10 1,657,883 0 (1,653,485)
Balance, beginning of period (in shares) at Dec. 31, 2025   97,866,996      
Balance, beginning of period at Dec. 31, 2025 27,288 $ 10 1,655,781 0 (1,628,503)
Statement of Stockholders' Equity (Deficit)          
Unrealized loss on marketable debt securities (6)        
Net loss (43,212)        
Balance, end of period (in shares) at Jun. 30, 2026   153,530,898      
Balance, end of period at Jun. 30, 2026 105,281 $ 15 1,776,987 (6) (1,671,715)
Balance, beginning of period (in shares) at Mar. 31, 2026   97,901,034      
Balance, beginning of period at Mar. 31, 2026 4,408 $ 10 1,657,883 0 (1,653,485)
Statement of Stockholders' Equity (Deficit)          
Issuance of common stock (in shares)   55,555,556      
Issuance of common stock 116,880 $ 5 116,875    
Exercise of stock options (in shares)   20,040      
Exercise of stock options 36   36    
Stock-based compensation expense 2,193   2,193    
Vesting of restricted common stock awards (in shares)   54,268      
Unrealized loss on marketable debt securities (6)     (6)  
Net loss (18,230)       (18,230)
Balance, end of period (in shares) at Jun. 30, 2026   153,530,898      
Balance, end of period at Jun. 30, 2026 $ 105,281 $ 15 $ 1,776,987 $ (6) $ (1,671,715)